LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
It is a key feature of NMR that the resonance frequency of nuclei in a particular sample substance is usually directly proportional to the strength of the applied magnetic field. It is this feature that is exploited in imaging techniques; if a sample is placed in a non-uniform magnetic field then the resonance frequencies of the sample's nuclei depend on where in the field they are located. This effect serves as the basis of magnetic resonance imaging. The principle of NMR usually involves three sequential steps:
Conversely, in rats, blood cholesterol is inversely correlated with cholesterol consumption: the more cholesterol a rat eats the lower the blood cholesterol. During the first seven hours after ingestion of cholesterol, as absorbed fats are being distributed around the body within extracellular water by the various lipoproteins (which transport all fats in the water outside cells), the concentrations increase. Plants make cholesterol in very small amounts. In larger quantities they produce phytosterols, chemically similar substances that compete with cholesterol for reabsorption in the intestinal tract, thus potentially reducing cholesterol reabsorption. When intestinal lining cells absorb phytosterols, in place of cholesterol, they usually excrete the phytosterol molecules back into the GI tract, an important protective mechanism. The intake of naturally occurring phytosterols, which encompass plant sterols and stanols, ranges between ≈200–300 mg/day depending on eating habits. Specially designed vegetarian experimental diets have been produced yielding upwards of 700 mg/day.
During the 2026 legislative session, Moore proposed an additional $150 million in cuts to the DDA as well as a $500,000 cap on the total amount of state funding a single person with a DDA waiver could receive in a year for their health needs. The Maryland Senate reduced these cuts to $126 million and rejected the health services cap, but retained several other cost containment measures proposed by Moore. In May 2025, Moore signed into law a bill requiring insurers to cover vaccinations recommended by the Advisory Committee on Immunization Practices as of December 2024. In September 2025, amid efforts by Health and Human Services Secretary Robert F. Kennedy Jr. to restrict access to vaccines, Maryland joined the Northeast Public Health Collaborative, a coalition of states to coordinate public health guidelines separate from the Centers for Disease Control and Prevention (CDC). During the 2026 legislative session, Moore introduced a bill that would give the Maryland Secretary of Health the ability to issue vaccine recommendations tied to guidance from major medical associations and other states. The bill passed and was signed into law by Moore in April 2026.
=== Sjögren syndrome === Sjögren syndrome (SS) is an autoimmune rheumatic disease of the exocrine glands. Increased incidence of SS after childbirth suggests a relationship between SS and pregnancy, and this led to the hypothesis that fetal microchimerism may be involved in SS pathogenesis. Studies showed the presence of Y-chromosome-positive fetal cells in minor salivary glands in 11 of 20 women with SS but in only one of eight normal controls. Fetal cells in salivary glands suggest that they may be involved in the development of SS.
== Chemical composition and reservoirs == Third-hand smoke and its components have been detected in various indoor environments. The possibility of nitrosamine formation on vehicular surfaces was identified via the spraying of "high but reasonable" levels of nitrous acid (about 4–12 times the levels typically found in homes) onto cellulose substrates and wiping surfaces in a vehicle that had experienced heavy smoking. Similar results were found when cellulose substrates were kept (without wiping) in the vehicle for three days when smoking occurred. Additionally, the persistence of various third-hand smoke components was quantified on wool, cotton, and polyester fibers with THS the most persistent on wool and least persistent on polyester. Washing clothing without detergent was found to remove some THS, though a substantial amount remained after standard laundering. Because of the growing resolving power and improved detection limits of analytical instruments (sometimes called the "vanishing zero" phenomenon), studies have demonstrated the transport of THS into other spaces via various media. For instance, third-hand smoke signatures have been detected in particles, which can effectively transport such compounds between indoor and outdoor air. Additionally, both gas-phase and aerosol-phase compounds linked to third-hand smoke were detected and quantified in a non-smoking movie theater, possibly via moviegoers' clothes and breath.
Sources: en.wikipedia.org
==== Image analysis ==== Both art-historical digital image processing and analog techniques have been applied to the shroud images. In 1976 scientists used imaging equipment from the American National Aeronautics and Space Administration (NASA) to analyze a photograph of the Shroud image and decoded the shroud image into a three-dimensional image. The optical physicist and former STURP member John Dee German has noted that it is not difficult to make a photograph which has 3D qualities. If the object being photographed is lit from the front, and a non-reflective "fog" of some sort exists between the camera and the object, then less light will reach and reflect back from the portions of the object that are farther from the lens, thus creating a contrast which is dependent on distance. The front image on the shroud is 1.95 metres (6 ft 5 in) long, and is not exactly the same size as the rear image, which is 2.02 metres (6 ft 8 in) long. Analysis of the images found them to be compatible with the shroud having been used to wrap a body 1.75 metres (5 ft 9 in) long. The image could be compared to oshiguma, the making of face-prints as an artform, in Japan. Furthermore, the subject's physical appearance corresponds to Byzantine iconography. The Shroud cloth is composed of threads of a nominal diameter of 0.15 mm, woven with fibers of linen with a diameter of about 10-20 μm. The Shroud image is a faint and superficial image caused by a translucent and discontinuous yellow discoloration of the fibers.
Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of hemoglobin subunit delta and hemoglobin subunit beta and raised levels of hemoglobin subunit gamma. It is an autosomal recessive disorder.
== Applications == Metamaterials are under consideration for many applications. Metamaterial antennas are commercially available. In 2007, one researcher stated that for metamaterial applications to be realized, energy loss must be reduced, materials must be extended into three-dimensional isotropic materials and production techniques must be industrialized. All-dielectric subwavelength metasurface focusing lens operating in the near infrared has been demonstrated by the Shalaev group in collaboration with the Raytheon team. This lens is currently used in Raytheon defense system products.
X-ray crystallography studies have been performed to determine the structure of aspartate transaminase from various sources, including chicken mitochondria, pig heart cytosol, and E. coli. Overall, the three-dimensional polypeptide structure for all species is quite similar. AST is dimeric, consisting of two identical subunits, each with approximately 400 amino acid residues and a molecular weight of approximately 45 kD. Each subunit is composed of a large and a small domain, as well as a third domain consisting of the N-terminal residues 3–14; these few residues form a strand, which links and stabilizes the two subunits of the dimer. The large domain, which includes residues 48–325, binds the PLP cofactor via an aldimine linkage to the ε-amino group of Lys258. Other residues in this domain—Asp222 and Tyr225—also interact with PLP via hydrogen bonding. The small domain consists of residues 15–47 and 326–410 and represents a flexible region that shifts the enzyme from an "open" to a "closed" conformation upon substrate binding. The two independent active sites are positioned near the interface between the two domains. Within each active site, a couple arginine residues are responsible for the enzyme's specificity for dicarboxylic acid substrates: Arg386 interacts with the substrate's proximal (α-)carboxylate group, while Arg292 complexes with the distal (side-chain) carboxylate. In terms of secondary structure, AST contains both α and β elements. Each domain has a central sheet of β-strands with α-helices packed on either side.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.